— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform — Demonstration of the Robust Predictive Power of CONVERGE® - 83% ...
Concerns about Lilly's Q3 update are overblown. Lilly's impressive growth story remains intact. The stock's valuation is attractive, factoring in anticipated growth over the next several years.
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Zacks.com users have recently been watching Lilly (LLY) quite a bit.
Here are the year’s notable fiction, poetry and nonfiction, chosen by the staff of The New York Times Book Review. By The New York Times Books Staff “The New India,” by Rahul Bhatia ...
Singer-songwriter Will Kennedy moves through grief in delicate and unsparing ways using the simple sounds of lo-fi indie rock. When the lily of the valley starts to bloom, it’s one of the surest ...
Local businessman Basim Sabri’s arrest and charging on three federal counts of bribery last Wednesday is only the latest piece of the puzzle. The tumult in City Hall began this summer when former 8th ...
Here are the year’s notable fiction, poetry and nonfiction, chosen by the staff of The New York Times Book Review. By The New York Times Books Staff Her Haight-Ashbury clothing store was ...
Join former prosecutor Andy McCarthy as he delves into the legal ins and outs of the latest Washington dramas with National Review editor in chief Rich Lowry. Capital Record – your weekly ...